Global Protein Therapeutics Market: Including Top Companies Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi

Global Protein Therapeutics Market is projected to reach $217,591 million by 2023, growing at a CAGR of 6.5% from 2017 to 2023. The monoclonal antibodies product segment occupied the highest market share of the market in 2016.

Therapeutic proteins are an important class of drugs, which serve patients in need of novel therapies. Approved recombinant protein therapeutics are developed to treat a wide array of clinical indications, including cancers, genetic disorders, infectious diseases, and metabolic disorders.

The major factors that drive the growth of the global protein therapeutics market include introduction & application of new plasma-derived therapies, surge in prevalence of chronic & life-threatening diseases, and rise in awareness among populace regarding the high efficiency of protein therapeutics. However, high cost of protein therapies and complex reimbursement scenario impede the market growth. Conversely, increase in novel indications for known protein therapeutics and untapped emerging markets are anticipated to provide lucrative opportunities for the manufacturers in this industry.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/60?utm_source=sy-Openpr

The report provides extensive competitive analysis and profiles of key market players, such as
• Abbott Laboratories
• Amgen Inc.
• Baxter International Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi

Other players (profiles not included in the report) in the value chain analysis include, Biogen, Inc., CSL Behring, and Genentech, Inc.

The metabolic disorders application generated the highest revenue of $27,837 million in 2016, and is anticipated to continue this trend in the future. This is attributed to the requirement for quality drugs and versatile therapies for disease treatment, especially diabetes. Cancer application is anticipated to grow at the highest CAGR of 8.2% from 2017 to 2023.

For More Information @ https://www.alliedmarketresearch.com/purchase-enquiry/60?utm_source=sy-Openpr

North America held the highest market share of $72,899 million in 2016, owing to high prevalence rate of cancer and other chronic diseases, owing to rise in adoption of these drugs and increase in awareness about protein therapeutics. Asia-Pacific is expected to grow at the highest CAGR of 7.6% during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

Key Findings of the Protein Therapeutics Market:
• The monoclonal antibody segment is anticipated to grow at the highest CAGR from 2017 to 2023.
• The cancer application segment is expected to witness the highest growth rate during the forecast period.
• Metabolic disease application segment is anticipated to occupy the largest share in the protein therapeutics market.
• North America dominated the global protein therapeutics market, and is projected to grow at a CAGR of 6.1%.

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/protein-therapeutics-market.html?utm_source=sy-Openpr

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.